Clinical Trials Logo
  1. Home
  2. Adverse Drug Reaction
  3. NCT03093818

PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions — PREPARE  

Adverse Drug Reaction Clinical Trial

Official title:
PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

Clinical Trial Summary

PREPARE is an international, prospective, multi-center, open, randomized, cross-over implementation study assessing the impact of pre-emptive pharmacogenomic testing, of a panel of actionable pharmacogenomic variants, on adverse event incidence. Additional outcomes include, healthcare expenditure, process indicators for implementation and provider adoption of pharmacogenomics.

Clinical Trial Description

Pre-emptive pharmacogenomic testing will be implemented in clinical sites across seven European countries (United Kingdom, The Netherlands, Austria, Greece, Slovenia, Italy and Spain). The 36-month study is split into two (19 and 18-month) time-blocks. The participating countries are randomized to start with either implementing pharmacogenomics guided prescribing or with standard of care in the first block. In the pharmacogenomics guided prescribing arm, results of the pharmacogenomic test will be incorporated in the (electronic) medical record and may be used by physicians and pharmacists to guide drug and dose selection for 39 routinely prescribed drugs, as per the Dutch Pharmacogenomics Working Group guidelines. In the standard of care arm, patients will not receive pharmacogenomic testing. After this 19-month block, the countries switch to implementing the opposite strategy and will recruit new patients for a period of 18 months. Patients are eligible for participation when they receive a first prescription for one or more of 39 drugs for which a Dutch Pharmacogenomic Working Group guideline is available (acenocoumarol, amitriptyline, aripiprazole, atomoxetine, atorvastatin, azathioprine ,capecitabine, citalopram, clomipramine, clopidogrel, codeine, doxepin, efavirenz, escitalopram, flecainide, flucloxacillin, fluorouracil, haloperidol, imipramine, irinotecan, mercaptopurine, metoprolol, nortryptiline, paroxetine, phenprocoumon, phenytoin, pimozide, propafenon, sertraline, simvastatin, tacrolimus, tamoxifen, tegafur, thioguanine, tramadol, venlafaxine, voriconazole, warfarin or zuclopenthixol). All patients will be followed for a minimum of three months and a maximum of 18 months. In total, 8,100 patients will be recruited; 4,050 will receive pharmacogenomic testing, and 4,050 will receive standard of care. Each implementation site will concentrate on, but is not limited to, recruiting patients within a specific therapeutic area. Therapeutic areas include primary care, general medicine, cardiology, oncology, psychiatry, neurology, and transplantation. It is hypothesized that implementing pharmacogenomics guided drug and dose selection will decrease incidence of clinically relevant adverse drug reactions by 30% (from 4% to 2.8% among those with actionable drug-gene interactions). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03093818
Study type Interventional
Source Leiden University Medical Center
Contact
Status Completed
Phase N/A
Start date March 20, 2017
Completion date May 1, 2021
View Details
See also
  Status Clinical Trial Phase
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT01946919 - Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Recruiting NCT04154553 - Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Completed NCT05224804 - Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
Completed NCT02297126 - A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program N/A
Not yet recruiting NCT04568668 - Evaluating ActionADE in Reducing Adverse Drug Reactions N/A
Recruiting NCT02012504 - Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Phase 0
Completed NCT01872520 - Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study N/A
Completed NCT01467050 - Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Phase 4
Completed NCT01679964 - Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study Phase 4
Completed NCT02094638 - Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study N/A
Recruiting NCT01906710 - the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes N/A
Completed NCT02888834 - Serious Adverse Drug Reaction and Their Preventability N/A
Completed NCT02838212 - Adverse Drug Reactions With Fatal Outcome N/A
Completed NCT02159209 - The Drug Induced Renal Injury Consortium N/A
Completed NCT02134587 - Educational Intervention in Pharmacovigilance for Hospital Health Professionals N/A
Completed NCT04553107 - Reducing Costs by Deprescribing Medications N/A
Recruiting NCT06219720 - The Texas Interprofessional Pharmacogenomics (IPGx)
Recruiting NCT05508763 - Personalised Therapeutics @LUMC